AOD-9604 Peptide: Complete Research Guide — Mechanisms, Studies & Analysis
Shop Top Peptides
Dihexa 20mg – 25 TabletsSign in to view catalog and pricing
Orforglipron 6mg – 100 TabletsSign in to view catalog and pricing
Clomid 50mg – 100 TabletsSign in to view catalog and pricing
BAM15 50mg – 60 TabletsSign in to view catalog and pricing
Cerebrolysin 60mgSign in to view catalog and pricing
Tesamorelin + Ipamorelin 11mg/6mg (17mg)Sign in to view catalog and pricingAOD 9604 Peptide Research: Complete Guide — Mechanisms, Studies & Analysis
Meta Description: AOD 9604 peptide is a modified HGH fragment 176-191 studied for fat metabolism, lipolysis, and cartilage repair. Explore the science, research findings, and quality standards.
Target Keywords: aod 9604 peptide, aod 9604, aod peptide, aod9604 peptide, aod-9604 peptide, aod-9604
Table of Contents
All products mentioned in this article are sold strictly for laboratory and research purposes only. Not for human consumption. This article is intended as a scientific literature review and does not constitute medical advice.
What Is AOD 9604 Peptide?
AOD 9604 peptide — formally known as Anti-Obesity Drug 9604 — is a synthetic peptide derived from a specific fragment of human growth hormone (hGH). Specifically, the AOD 9604 peptide corresponds to amino acids 176–191 of the 191-amino-acid hGH polypeptide, with the addition of an N-terminal tyrosine residue that stabilizes the peptide structure [1, 2]. This makes AOD-9604 a hexadecapeptide (16 amino acids) with the following sequence:
Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe
The molecular formula of the AOD 9604 peptide is C₇₈H₁₂₃N₂₃O₂₃S₂, with a molecular weight of approximately 1,815.1 Daltons. A critical structural feature is the disulfide bond formed between the two cysteine residues at positions 7 and 14 (Cys₁₈₂ and Cys₁₈₉ in the full hGH numbering), which cyclizes the molecule and maintains its three-dimensional conformation. Research has demonstrated that this 3D structure closely resembles the homologous region within the complete hGH protein [2, 3].
What makes the AOD 9604 peptide particularly noteworthy in the research community is its ability to replicate certain metabolic activities of full-length human growth hormone — specifically those related to fat metabolism — without inducing the growth-promoting or diabetogenic effects associated with hGH administration [4, 5]. This separation of metabolic function from growth-related activity has made the AOD peptide one of the most studied hGH-derived fragments in preclinical and clinical research settings. While AOD 9604 is often marketed as a fat-burning peptide, its effectiveness is generally considered modest compared to other peptides such as GLP-1 agonists and growth hormone secretagogues, which may have more pronounced effects on fat loss and metabolic health.
The peptide is produced through synthesis method and is typically supplied in lyophilized (freeze-dried) powder form for research purposes, primarily as a research chemical for laboratory use and for research applications. AOD 9604 is also studied as part of broader peptide research research, where peptide research is explored for its potential benefits in metabolic health and fat loss. Understanding its structure, origin, and mechanism of action requires a deeper examination of its development history and the scientific evidence accumulated over more than two decades of investigation.
This article is intended for educational and informational purposes only.
The History and Development of AOD-9604
The story of AOD-9604 begins at Monash University in Melbourne, Australia, where Professor Frank Ng and his research team first identified that specific fragments of human growth hormone possessed distinct biological activities independent of the whole protein. Throughout the 1990s, Professor Ng’s laboratory systematically investigated various C-terminal fragments of hGH, seeking to isolate the lipolytic (fat-metabolizing) domain from the growth-promoting and diabetogenic domains [6, 7]. The commercial development and clinical trials of AOD-9604 were subsequently undertaken by Metabolic Pharmaceuticals Ltd., which played a central role in conducting rigorous research, including Phase I and II trials, to evaluate the safety, efficacy, and metabolic effects of the compound.
The Foundational Discovery
The initial breakthrough came when Wu and Ng published their findings in 1993, demonstrating that the synthetic C-terminal sequence comprising amino acids 177–191 of human growth hormone exhibited antilipogenic action — the ability to inhibit the conversion of non-fatty food substances into body fat [6]. This was significant because it suggested that the fat-metabolizing activity of hGH could be localized to a specific structural domain rather than requiring the entire 191-amino-acid protein.
Subsequent work by Natera, Jiang, and Ng in 1994 demonstrated that chronic treatment with synthetic hGH 177–191 peptide produced reductions in cumulative body weight gain and adipose tissue mass in obese mice [7]. These early animal studies laid the groundwork for a more optimized peptide candidate.
From Fragment to AOD9604
The modified fragment that would become known as AOD9604 incorporated the key innovation of adding a tyrosine residue at the N-terminal end of the hGH 177–191 sequence. This modification improved peptide stability and provided a convenient site for radiolabeling in research applications. The “AOD” designation stands for “Anti-Obesity Drug,” reflecting the original research intent, while “9604” served as the internal development code assigned by the Monash University research program.
Metabolic Pharmaceuticals and Clinical Development
The commercial development rights for AOD9604 were licensed to Metabolic Pharmaceuticals Pty Ltd, a Melbourne-based biopharmaceutical company. Under their stewardship, the AOD 9604 peptide progressed through a comprehensive preclinical and clinical development program that included:
Multiple preclinical efficacy studies in rodent models of obesity
Comprehensive genotoxicity testing (Ames test, chromosomal aberration assay, bone marrow micronucleus assay)
Chronic toxicology studies in rats (6 months) and cynomolgus monkeys (9 months)
Pharmacokinetic characterization studies in pigs and rats
Six clinical trials: These were randomized, double-blind, placebo-controlled studies involving approximately 900 participants, conducted over several years, and contributed to a robust safety and efficacy data set for AOD-9604 [8, 9, 10]
The clinical program culminated in two Phase IIb trials involving 300 and 500 obese adults, respectively. While the peptide demonstrated an excellent safety profile indistinguishable from placebo, the final efficacy trial — which incorporated an intensive diet and exercise regimen across all groups — did not achieve statistically significant weight reduction compared to the placebo group [8]. Earlier trials had shown moderate weight reduction effects, particularly focused on abdominal fat, similar in magnitude to that observed with full-length hGH in published studies.
Modern Research Directions
Following the obesity clinical program, research interest in AOD-9604 has expanded into new areas, most notably cartilage repair and osteoarthritis research. The peptide’s ability to stimulate chondrocyte differentiation and proteoglycan synthesis has opened new avenues of investigation [11], reflecting the broader scientific trend of discovering additional biological functions for growth hormone–derived peptide fragments.
The Science Behind AOD 9604: How It Works
Understanding the mechanism of action of the AOD 9604 peptide requires examining its effects at the molecular, cellular, and systemic levels. While the complete mechanism remains an active area of research, decades of study have elucidated several key pathways through which this AOD peptide exerts its biological effects.
AOD 9604 stimulates lipolysis through beta-3 adrenergic receptors on fat cells, accelerating the breakdown of stored triglycerides into free fatty acids for energy while inhibiting lipogenesis, the formation of new fat stores. This action directly influences adipose tissue metabolism, promoting fat oxidation and supporting fat metabolism as part of a comprehensive approach involving diet, exercise, and lifestyle changes. Preclinical studies have shown that AOD 9604 increases lipid oxidation, further supporting its role in enhancing adipose tissue metabolism and supporting fat metabolism as part of a holistic approach to fat loss.
AOD 9604 is often promoted for its potential to target stubborn fat areas that are resistant to diet and exercise. Due to these effects, AOD 9604 is often described as a fat burning peptide, as it selectively promotes lipolysis and facilitates body recomposition without significant muscle loss or the adverse effects typically associated with growth hormone therapies.
Lipolysis Stimulation
The primary mechanism investigated for AOD-9604 involves the stimulation of lipolysis — the breakdown of stored triglycerides in adipose tissue into free fatty acids and glycerol. Research by Ng and colleagues demonstrated that the AOD 9604 peptide activates lipolytic pathways in adipocytes (fat cells) in a manner analogous to full-length hGH, but through a distinct signaling mechanism [4, 12].
In studies using obese Zucker rats, AOD9604 was shown to:
Stimulate the release of glycerol from isolated adipose tissue, indicating enhanced triglyceride breakdown [4]
Increase fat oxidation rates in chronically treated obese animals, as measured by respiratory exchange ratio [5]
Reduce body weight gain through reduced adipose tissue accumulation rather than lean mass loss [5, 12]
Lipogenesis Inhibition
In addition to promoting fat breakdown, the AOD 9604 peptide has been shown to inhibit lipogenesis — the metabolic process by which the body converts carbohydrates and other substrates into stored fat. Specifically, research indicates that AOD-9604 inhibits acetyl-CoA carboxylase activity in both hepatocytes (liver cells) and adipocytes [4, 6]. Acetyl-CoA carboxylase is a rate-limiting enzyme in the de novo fatty acid synthesis pathway, and its inhibition reduces the formation of new fatty acids from non-lipid precursors.
This dual mechanism — simultaneously enhancing fat breakdown while reducing new fat formation — distinguishes the AOD peptide from many other compounds studied for metabolic applications. The net effect observed in preclinical models is a shift in the energy balance toward fat utilization rather than fat storage.
The Beta-3 Adrenergic Receptor Connection
One of the most compelling mechanistic findings involves the relationship between AOD-9604 and the beta-3 adrenergic receptor (β₃-AR). In a pivotal study published in Endocrinology in 2001, Heffernan, Summers, Thorburn, and Ng examined the effects of both hGH and AOD9604 on lipid metabolism in obese wild-type mice compared to β₃-AR knock-out mice [12].
Key findings from this research include:
Both hGH and AOD9604 upregulated β₃-AR mRNA expression in white adipose tissue of obese mice
The fat-reducing effects of both compounds were significantly attenuated in β₃-AR knock-out animals
AOD9604 appeared to partially function by restoring the suppressed levels of β₃-AR RNA expression that are characteristic of the obese phenotype [12, 13]
The β₃-AR is predominantly expressed in adipose tissue and plays a central role in regulating lipolysis and thermogenesis. By increasing β₃-AR expression, the AOD 9604 peptide may restore the adipose tissue’s sensitivity to catecholamine-stimulated lipolysis, which is typically impaired in obesity.
Independence from the Growth Hormone Receptor
A critical distinction between AOD-9604 and full-length hGH lies in their receptor interactions. Ligand binding experiments have confirmed that AOD9604 is not a high-affinity ligand for the growth hormone receptor (GHR) [5, 13]. This finding has important implications:
AOD-9604 does not stimulate IGF-1 (Insulin-Like Growth Factor-1) production, which is the primary mediator of hGH’s growth-promoting effects [8, 9]
The peptide does not induce the diabetogenic effects associated with GHR activation [8]
The metabolic effects of AOD-9604 must be mediated through an alternative pathway — one that involves the β₃-AR system rather than the classical GHR/IGF-1 axis
This mechanistic independence is what gives the AOD 9604 peptide its unique research profile: it retains the fat-metabolizing properties of the C-terminal domain of hGH while lacking the growth-promoting, insulin-antagonizing, and potentially proliferative effects mediated through the GHR.
Effects on Energy Metabolism
Research in obese mouse models has demonstrated that chronic treatment with AOD9604 produces measurable changes in whole-body energy metabolism. Heffernan et al. (2001) reported that AOD9604 treatment increased fat oxidation rates, as evidenced by changes in the respiratory quotient, without significantly affecting total energy expenditure or food intake [5]. This suggests that the peptide shifts the substrate utilization pattern toward greater reliance on fatty acids as fuel, rather than simply reducing caloric intake or increasing energy expenditure.
AOD 9604 vs. Full-Length Human Growth Hormone
Understanding how the AOD 9604 peptide differs from full-length growth hormone is essential for appreciating its research significance. While both compounds influence fat metabolism, their broader biological profiles diverge substantially.
Parameter | Full-Length hGH (191 aa) | AOD 9604 Peptide (16 aa) |
|---|---|---|
Molecular Weight | ~22 kDa | ~1.8 kDa |
IGF-1 Stimulation | Yes — primary mechanism for growth effects | No — does not affect IGF-1 levels [8] |
Lipolytic Activity | Yes | Yes — comparable in preclinical models [5] |
Anti-Lipogenic Activity | Limited | Yes — inhibits acetyl-CoA carboxylase [4, 6] |
Glucose Tolerance Effects | Impairs glucose tolerance; can cause insulin resistance | No negative effect on carbohydrate metabolism [8] |
Growth Promotion | Yes — stimulates growth in multiple tissues | No growth-promoting effects observed [8, 9] |
GH Receptor Binding | High-affinity binding | Not a high-affinity GHR ligand [5] |
β₃-AR mRNA Upregulation | Yes | Yes [12] |
Immunogenicity | Can produce antibodies | No anti-AOD9604 antibodies detected in studies [8, 9] |
Plasma Half-Life | ~21 minutes | ~3 minutes (IV) [10] |
In contrast, AOD 9604 does not stimulate growth hormone release or IGF-1, and does not share these risks, making it distinct in its safety profile.
This comparison highlights why the AOD peptide has attracted considerable research interest: it isolates the fat-metabolizing domain of hGH into a small, non-immunogenic peptide fragment that does not carry the metabolic baggage of the full length growth hormone, such as fluid retention or carpal tunnel syndrome. For researchers studying fat metabolism pathways, this specificity makes AOD-9604 a valuable investigational tool.
AOD 9604 is often marketed as a fat burning peptide, but its mechanism and safety profile differ significantly from full length growth hormone.
For scientists exploring the range of growth hormone–derived peptides, Iron Peak Peptides offers a comprehensive peptide glossary that covers related compounds including Sermorelin and other GH-related research peptides.
Key Research Findings on AOD 9604 Peptide
Clinical trial data and research literature provide clinical evidence for AOD 9604‘s effects, with early studies laying the groundwork for later, more robust investigations. The body of research on AOD 9604 spans more than two decades and includes preclinical studies in multiple animal models, comprehensive toxicological assessments, pharmacokinetic characterization, and human clinical trials. Notably, six randomized controlled trials involving over 900 participants have demonstrated excellent safety and tolerability for AOD-9604, with no serious adverse events attributed to the peptide. Clinical trials have shown that AOD 9604 produces modest fat loss—approximately 2.6 kg of fat loss over 12 weeks compared to placebo—while other peptides like Tesamorelin have demonstrated more significant fat loss, particularly in reducing visceral fat. Research outcomes often focus on changes in body fat mass and achieving body composition goals, with early studies providing foundational support for these endpoints before being validated by larger clinical trials. Below is a systematic review of the major research findings, organized by area of investigation.
Fat Metabolism and Body Composition Research
The earliest and most extensive body of research on the AOD 9604 peptide focuses on its effects on lipid metabolism and body composition. These studies established the foundational understanding of the peptide’s biological activity.
Obese Zucker Rat Studies (2000)
Ng and colleagues at Monash University published a seminal study in Hormone Research (2000) examining the metabolic actions of AOD9604 in obese Zucker rats. The study demonstrated that:
AOD9604 significantly stimulated lipolysis in adipose tissue explants
The peptide inhibited the incorporation of acetate into lipid (lipogenesis) in both liver and adipose tissue
These effects were observed at concentrations relevant to those achievable through chronic administration
The metabolic effects were comparable to those produced by intact hGH [4]
A complementary study published in the Journal of Molecular Endocrinology (2000) by Ng, Jiang, Gianello, Pitt, and Roupas further characterized the molecular and cellular actions of the hGH C-terminal domain in Zucker fatty rats. This research identified the upregulation of β₃-adrenoreceptor RNA expression as a potential mechanism of action [13].
Oral Administration in Obese Mice (2000)
Heffernan, Jiang, Thorburn, and Ng published research in the American Journal of Physiology – Endocrinology and Metabolism (2000) demonstrating that AOD9604 was effective when administered orally in obese mice. Key findings included:
Oral AOD9604 produced significant reductions in body fat accumulation
The peptide altered lipid metabolism parameters, with increased markers of fat oxidation
The study provided early evidence supporting the oral bioavailability of the peptide [14]
Chronic Treatment in ob/ob Mice (2001)
A landmark study by Heffernan, Thorburn, Fam, Summers, Conway-Campbell, Waters, and Ng, published in the International Journal of Obesity (2001), evaluated the effects of chronic hGH and AOD9604 treatment in genetically obese (ob/ob) mice over 14 days. The results showed:
Both hGH and AOD9604 reduced body weight gain and total body fat
Unlike hGH, AOD9604 did not cause increases in IGF-1 levels or changes in glucose homeostasis
The fat-reducing effects were primarily observed in obese, not lean, animals [5]
β₃-Adrenergic Receptor Knockout Studies (2001)
The mechanistic investigation by Heffernan et al. in Endocrinology (2001) using β₃-AR knockout mice provided the strongest evidence for the receptor pathway involved. The study demonstrated that the lipolytic effects of AOD9604 were significantly reduced in mice lacking the β₃-adrenergic receptor, confirming that this receptor plays a key role in mediating the peptide’s fat-metabolizing activity [12].
Cartilage Repair and Osteoarthritis Research
A newer and rapidly expanding area of AOD-9604 research involves its potential effects on cartilage tissue and joint health. This research direction has generated significant scientific interest.
Rabbit Osteoarthritis Model (2015)
The study produced several noteworthy findings:
Histological analysis demonstrated improved cartilage morphology, increased proteoglycan content, and reduced cartilage degradation markers
This study opened a significant new research avenue for the AOD 9604 peptide, suggesting that its biological activity extends beyond adipose tissue to include effects on chondrocyte function and cartilage matrix synthesis.
Chondrogenic Differentiation Research
Subsequent investigations have explored the mechanisms by which AOD-9604 may influence cartilage biology. Preclinical evidence has indicated that the peptide can:
Stimulate chondrocyte differentiation — promoting the development of cartilage-producing cells
Increase proteoglycan synthesis — the major structural components of cartilage extracellular matrix
Reduce expression of inflammatory markers associated with cartilage destruction in osteoarthritis models [11, 15]
These findings have spurred ongoing research into AOD-9604 as a potential research tool for studying cartilage regeneration pathways, making it relevant to the growing field of musculoskeletal peptide science.
Pharmacokinetic Research
Understanding the absorption, distribution, metabolism, and excretion of AOD-9604 has been the subject of several detailed studies, primarily conducted in animal models.
Plasma Degradation Kinetics
In vitro studies demonstrated that AOD9604 undergoes rapid sequential N-terminal amino acid removal in plasma. The half-life in rat plasma at room temperature was approximately 4 minutes, with the peptide becoming undetectable after 56 minutes. The primary degradation products identified by mass spectrometry analysis were N-terminal truncated fragments (designated -1aa, -2aa, -3aa, etc.), with no C-terminal truncation observed beyond the disulfide bridge [10].
Importantly, some of these degradation fragments — particularly the -2aa and -3aa truncated forms — retained measurable anti-lipogenic activity in vitro, suggesting that the biological activity may persist beyond the presence of the intact peptide [10].
Pig Pharmacokinetic Studies
Pharmacokinetic characterization in pigs provided the following data:
Whole-Body Radiography
Rat whole-body radiography studies using ¹⁴C-labeled AOD9604 revealed distribution to virtually all non-CNS tissues, with principal sites of localization in the pancreas, pineal body, thyroid, liver, and kidney cortex. Similar organ distribution patterns were observed following both IV and oral administration. The study estimated approximately 40% oral bioavailability [10].
AOD-9604 in Current Scientific Literature
The research landscape for AOD-9604 continues to evolve, with several active areas of investigation expanding upon the foundational work completed over the past two decades.
Expanding Applications in Musculoskeletal Research
The discovery of AOD-9604‘s effects on cartilage biology has opened substantial new research directions. The 2015 rabbit osteoarthritis study [11] has catalyzed further investigation into:
Combination approaches with hyaluronic acid and other matrix-supporting compounds
Molecular pathway elucidation identifying the specific signaling cascades through which AOD-9604 influences chondrocyte behavior
Comparative studies evaluating AOD-9604 alongside other peptides being investigated for cartilage-related applications
A 2024 review article in International Journal of Molecular Sciences examining peptides for targeting chondrogenic induction and cartilage repair highlighted AOD9604 among a select group of compounds showing promise in preclinical osteoarthritis models [15].
Anti-Doping and Detection Science
AOD-9604‘s inclusion on the World Anti-Doping Agency (WADA) Prohibited List under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) as a “growth hormone fragment” has driven a parallel body of research focused on detection methodology [16, 17].
Thomas, Marchand, Grognet, Terlain, and colleagues (2014) published research in Drug Testing and Analysis characterizing the in vitro metabolism of AOD9604 using liquid chromatography–high-resolution mass spectrometry (LC-HRMS), providing analytical methods for detecting the peptide and its metabolites in biological samples [16].
Bidlingmaier et al. (2013) also published in Drug Testing and Analysis demonstrating that AOD-9604 does not cross-react with the WADA hGH isoform immunoassay, requiring specific detection methods for its identification [17].
Safety and Nutraceutical Research
More recent studies have examined AOD9604 from a safety and regulatory science perspective. Moré and Kenley published comprehensive safety and metabolism data from non-clinical studies of AOD9604 in the Journal of Endocrinology and Metabolism, covering:
Genotoxicity testing (Ames test, chromosomal aberration assay, bone marrow micronucleus assay) — all negative
Pharmacokinetic data confirming oral bioavailability with rapid degradation kinetics [10]
These safety data have contributed to AOD9604 receiving Generally Recognized as Safe (GRAS) status determination by a qualified panel of experts for its intended use in foods, drinks, and dietary supplements [10, 18].
Safety and Tolerability Profile of AOD9604
The safety profile of AOD9604 is among the most thoroughly characterized of any peptide in its class, supported by comprehensive non-clinical toxicology programs and six Phase I and Phase II clinical trials involving approximately 900 participants in a clinical setting. The most commonly reported adverse effects in clinical trials were mild headaches and gastrointestinal symptoms, which occurred at rates similar to placebo groups, indicating a favorable tolerability profile.
When considering a peptide protocol, it is essential that clinical use of AOD 9604 be supervised by a qualified healthcare provider or licensed medical professional. Any protocol should be tailored to the individual’s health status and monitored for safety concerns, especially in those with metabolic syndrome or cardiovascular disease. Safety monitoring should include tracking metabolic parameters such as blood glucose, blood sugar, and insulin sensitivity. Notably, AOD 9604 does not negatively impact insulin sensitivity or blood glucose levels, making it suitable for individuals with certain health status concerns. This careful approach ensures that the benefits and risks are appropriately managed in a clinical setting.
Non-Clinical Safety Summary
The preclinical safety program, sponsored by Metabolic Pharmaceuticals and conducted at multiple GLP-compliant research facilities across the United Kingdom and Australia, included the following studies:
Genotoxicity Testing:
Chromosomal aberration assay (1999): No clastogenic activity in Chinese Hamster Ovary (CHO) cells. An observation of increased polyploidy at very high concentrations was noted but considered not biologically significant [10]
Chronic Toxicology:
Clinical Safety Summary
Across six randomized, double-blind, placebo-controlled human trials, Stier, Vos, and Kenley (2013) reported:
AOD9604 displayed a safety and tolerability profile indistinguishable from placebo
No effect on serum IGF-1 levels — confirming the peptide does not act through the IGF-1 pathway
No impairment of glucose tolerance — oral glucose tolerance testing showed no adverse metabolic effects
No immunogenicity — no anti-AOD9604 antibodies detected in any subjects
No serious adverse events related to AOD9604 administration
No withdrawals due to AOD9604-related adverse effects [8]
This comprehensive safety record — spanning in vitro genotoxicity testing, chronic animal toxicology across two species, and controlled human clinical trials — represents one of the most thorough safety characterizations available for any research peptide.
Regulatory Status and Classification
The regulatory classification of AOD-9604 is multifaceted and varies by jurisdiction and intended use. Importantly, AOD 9604 is not approved for fat loss, weight management, or any other medical uses. Researchers should be aware of the following regulatory considerations:
GRAS Status
AOD9604 has received a Generally Recognized as Safe (GRAS) determination by a panel of qualified experts for its intended use as an ingredient in foods, drinks, and dietary supplements. This determination was based on the extensive non-clinical safety data described above and the favorable human clinical safety profile [10, 18].
WADA Prohibited Status
The World Anti-Doping Agency (WADA) classifies AOD-9604 as a prohibited substance under Section S2.2.3 of the Prohibited List, categorized as a “growth hormone fragment.” This classification applies at all times, both in- and out-of-competition, for athletes subject to WADA testing [19]. Researchers should be aware of this classification when designing studies involving athletic populations.
FDA Regulatory Considerations
In the United States, AOD-9604 is not approved as a pharmaceutical drug by the FDA. It has been the subject of regulatory discussions regarding its classification under the Federal Food, Drug, and Cosmetic Act, particularly regarding pharmacy compounding applications. The FDA Pharmacy Compounding Advisory Committee has reviewed AOD-9604 in the context of bulk drug substance nominations [18].
Research Use Classification
For research purposes, AOD 9604 peptide is available as a research chemical. All purchases should comply with applicable federal, state, and local regulations governing the acquisition and use of research materials.
Quality Standards and Purity Verification for AOD 9604
The analytical quality of research-grade AOD 9604 peptide is paramount for obtaining reliable and reproducible experimental results. Given the peptide’s structural complexity — including its disulfide bond, multiple chiral centers, and susceptibility to degradation — rigorous quality control is essential.
Critical Quality Attributes
Purity Assessment via HPLC:
High-Performance Liquid Chromatography (HPLC) remains the gold standard for peptide purity assessment. Research-grade AOD 9604 peptide should demonstrate ≥98% purity by HPLC analysis, with premium-grade material achieving high quality. The HPLC method should resolve the intact cyclic peptide from:
Linear (reduced) forms lacking the disulfide bond
N-terminal truncation products (the primary degradation pathway)
Deletion sequences from synthesis errors
Oxidized variants
Mass Spectrometric Confirmation:
Mass spectrometry (MS) analysis should confirm the molecular weight of the peptide (1,815.1 Da for the free acid form) and verify the amino acid sequence. Electrospray ionization mass spectrometry (ESI-MS) or matrix-assisted laser desorption ionization (MALDI-MS) are standard techniques for this purpose.
Disulfide Bond Verification:
Given the critical importance of the Cys₁₈₂-Cys₁₈₉ disulfide bond for maintaining the biologically active conformation of AOD-9604, quality control should include verification that the peptide is in the oxidized (cyclized) form rather than the reduced (linear) form. This can be assessed through comparative HPLC analysis under reducing and non-reducing conditions.
Amino Acid Analysis:
Quantitative amino acid analysis provides an independent confirmation of peptide identity and composition, serving as a complementary technique to mass spectrometry.
Endotoxin Testing:
For research applications involving cell culture or in vivo animal studies, endotoxin testing (typically via the Limulus Amoebocyte Lysate [LAL] assay) ensures that bacterial endotoxin contamination does not confound experimental results.
Iron Peak Peptides maintains rigorous quality standards for all research peptides, including AOD 9604, with third-party quality assurance documentation available for each production lot.
How to Evaluate AOD 9604 Peptide Quality for Research
Selecting a reliable source of AOD 9604 peptide for research applications requires careful evaluation. The following criteria should guide researchers in assessing peptide quality and supplier reliability:
quality assurance Requirements
A comprehensive quality assurance for AOD 9604 peptide should include:
HPLC purity data with the chromatogram showing clear peak resolution (purity ≥98%)
Mass spectrometry data confirming molecular weight within ±1 Da of the theoretical value (1,815.1 Da)
Appearance description (white to off-white lyophilized powder is expected)
Peptide content (net peptide percentage, accounting for counter-ions, moisture, and residual solvents)
Lot number and manufacture date for traceability
Storage recommendations specific to the production lot
Red Flags in Peptide Quality
Researchers should be cautious of suppliers who:
Cannot provide a lot-specific quality assurance
List purity only by UV absorbance without HPLC data
Do not confirm molecular weight by mass spectrometry
Offer prices significantly below market rates (suggesting compromised synthesis quality or incorrect peptide content)
Cannot provide information about their synthesis and purification methods
Lack quality standards verification
The Importance of Third-Party Testing
Independent, third-party analytical testing provides an additional layer of quality assurance beyond in-house testing by the manufacturer. Third-party testing by an accredited analytical laboratory ensures unbiased verification of:
Peptide identity (correct sequence)
Purity levels (free from synthesis impurities)
Disulfide bond integrity (correct folding)
Absence of contaminating substances
When you buy peptides online for research applications, always verify that the supplier provides comprehensive, lot-specific documentation from quality standards facilities.
Comparing AOD 9604 Sources: What Sets IronPeak Apart
In the competitive landscape of research peptide suppliers, the quality differences between sources can be substantial. Iron Peak Peptides distinguishes itself through several key commitments:
Manufacturing Standards
All Iron Peak Peptides products, including AOD 9604, are produced using validated synthesis method protocols by experienced manufacturing partners. The synthesis of AOD-9604 is particularly demanding due to:
The requirement for precise disulfide bond formation between the two cysteine residues
The N-terminal tyrosine modification that must be correctly incorporated
The need for high-efficiency coupling reactions across all 16 amino acid positions
Rigorous purification to remove incomplete sequences and side-products
Purity Commitment
Iron Peak Peptides maintains a minimum purity standard of ≥98% for AOD 9604, with many production lots achieving high quality. Each lot undergoes multi-method analytical verification including HPLC, mass spectrometry, and amino acid analysis.
Transparent Documentation
Every product shipped includes a . Researchers receive full analytical documentation supporting the identity, purity, and quality of their research materials.
Research Support
Iron Peak Peptides provides comprehensive scientific documentation and educational resources to support the research community. The peptide glossary and product-specific information pages serve as valuable references for researchers new to peptide science.
For researchers working with growth hormone–related peptides, IronPeak also offers related compounds such as HGH Fragment 176-191 and Sermorelin, enabling comprehensive investigation of GH-axis peptides.
Proper Storage and Handling for Research Use
The stability and biological activity of AOD 9604 peptide are directly influenced by storage conditions and handling practices. Proper protocols are essential for maintaining peptide integrity throughout the research timeline.
Lyophilized Storage
AOD 9604 is typically supplied as a lyophilized (freeze-dried) powder. In this form, the peptide exhibits good stability when stored correctly:
Long-term storage: -20°C or below, in sealed vials protected from moisture and light
Short-term storage (weeks to a few months): 2–8°C (standard refrigeration) is acceptable for unopened vials
Shelf life: Properly stored lyophilized AOD 9604 typically maintains stability for 24+ months at -20°C
Desiccation: Use desiccant packs in the storage container to minimize moisture exposure
Handling Precautions
Wear appropriate personal protective equipment (PPE) including gloves and eye protection
Handle lyophilized powder in a low-humidity environment when possible
Degradation Considerations
As demonstrated in the pharmacokinetic research by Moré and Kenley, AOD9604 undergoes rapid N-terminal amino acid truncation in biological matrices [10]. Researchers should account for this degradation pathway when:
Designing in vitro experiments with extended incubation times
Interpreting pharmacokinetic data from in vivo studies
Selecting appropriate analytical methods for detecting both the intact peptide and its truncation products
Frequently Asked Questions About AOD 9604 Peptide
What exactly is AOD 9604 peptide and where does it come from?
AOD 9604 peptide (Anti-Obesity Drug 9604) is a synthetic hexadecapeptide corresponding to amino acids 176–191 of human growth hormone, with an additional N-terminal tyrosine residue. It was originally developed by Professor Frank Ng and his research team at Monash University in Melbourne, Australia. The peptide was designed to isolate the lipolytic (fat-metabolizing) domain of hGH without the growth-promoting or diabetogenic properties of the full hormone. It is produced through synthesis method and features a disulfide bond between two cysteine residues that maintains its biologically active three-dimensional conformation [1, 2, 4].
How does the AOD 9604 peptide mechanism of action differ from full human growth hormone?
The fundamental difference lies in receptor interactions and downstream signaling. Full-length hGH binds to the growth hormone receptor (GHR), activating the JAK-STAT signaling pathway, which leads to IGF-1 production, cell growth, and metabolic effects — including potentially adverse effects like insulin resistance and glucose intolerance. The AOD 9604 peptide does not bind to the GHR with high affinity and does not stimulate IGF-1 production [5, 8, 12]. Instead, research suggests AOD-9604 exerts its fat-metabolizing effects through upregulation of β₃-adrenergic receptor expression in adipose tissue, promoting lipolysis and inhibiting lipogenesis via inhibition of acetyl-CoA carboxylase — all without affecting growth pathways or carbohydrate metabolism [4, 12, 13].
What is the current research on AOD-9604 and cartilage repair?
Preclinical evidence suggests AOD-9604 may stimulate chondrocyte differentiation and increase proteoglycan synthesis — both essential processes for cartilage maintenance and repair [11, 15]. This research area is currently active, with ongoing investigations exploring the peptide’s potential role in musculoskeletal applications.
Is AOD 9604 peptide the same as HGH Fragment 176-191?
AOD 9604 and HGH Fragment 176-191 are closely related but not identical. Both correspond to the C-terminal region of human growth hormone spanning amino acids 176–191. However, AOD 9604 specifically includes an additional tyrosine residue at the N-terminus (making it amino acids Tyr + 177–191), which stabilizes the peptide and aids in research applications such as radiolabeling. The native HGH Fragment 176-191 begins at position 176 (phenylalanine) without the added tyrosine. While both peptides share similar biological activities in preclinical models, the majority of published clinical and safety data pertains specifically to the AOD9604 formulation with the N-terminal tyrosine 1, 2]. Iron Peak Peptides offers both [AOD 9604 and HGH Fragment 176-191 for research applications.
What is the GRAS status of AOD-9604 and what does it mean?
AOD9604 has received a Generally Recognized as Safe (GRAS) determination from a qualified expert panel for its intended use in foods, drinks, and dietary supplements [10, 18]. GRAS status means that a substance is generally recognized, among qualified experts, as having been adequately shown to be safe under the conditions of its intended use. This determination was based on the extensive preclinical safety data (including negative genotoxicity testing, 6-month rat toxicology, and 9-month primate toxicology studies) and the favorable safety profile observed across six human clinical trials. It is important to note that GRAS status for food use is distinct from FDA drug approval, and AOD-9604 is not approved as a pharmaceutical product.
Why is AOD-9604 on the WADA Prohibited List?
The World Anti-Doping Agency (WADA) classifies AOD-9604 as a prohibited substance under Section S2.2.3 of the Prohibited List, categorized among “growth hormone fragments” [19]. This prohibition applies at all times, both in- and out-of-competition. WADA’s rationale is based on the peptide’s derivation from human growth hormone and its demonstrated biological activity on fat metabolism, which falls within the category of substances that could potentially provide performance or body composition advantages to athletes. Researchers conducting studies involving athletic populations must account for this classification in their experimental designs and institutional review processes.
What purity level should researchers look for when purchasing AOD 9604 peptide?
For reliable research results, AOD 9604 peptide should have a minimum purity of ≥98% as determined by High-Performance Liquid Chromatography (HPLC). Premium research-grade material typically achieves high quality. Beyond the HPLC purity percentage, researchers should verify that the supplier provides mass spectrometry data confirming the correct molecular weight (1,815.1 Da), evidence of disulfide bond formation (cyclized rather than linear form), and endotoxin testing for applications involving cell culture or in vivo studies. A comprehensive, lot-specific quality assurance from a reputable supplier like Iron Peak Peptides should include all of this analytical documentation.
How should AOD 9604 be stored to maintain stability for research?
Lyophilized AOD 9604 peptide should be stored at -20°C or below for long-term stability (24+ months), with protection from moisture and light. Short-term storage at 2–8°C is acceptable for unopened vials over periods of weeks to a few months. Repeated freeze-thaw cycles should be avoided, as they can promote peptide degradation and aggregation. Given that AOD9604 undergoes rapid N-terminal amino acid truncation in biological matrices (half-life of approximately 4 minutes in rat plasma) [10], researchers should prepare working solutions fresh and consider using protease inhibitor cocktails in experimental buffers where prolonged incubation is required.
What future research directions are being explored for AOD-9604?
Current and emerging research directions for AOD-9604 include: (1) expanded investigation of cartilage repair and osteoarthritis applications, including combination studies with hyaluronic acid and other chondroprotective agents [11, 15]; (2) further elucidation of the β₃-adrenergic receptor–mediated mechanism of action and its downstream signaling pathways [12, 13]; (3) investigation of metabolically active truncation products (particularly the -2aa and -3aa fragments) that retain biological activity [10]; (4) analytical chemistry advances for improved detection methodology in biological matrices [16, 17]; and (5) exploration of potential synergistic effects with other research peptides targeting related metabolic or musculoskeletal pathways. The breadth of ongoing research reflects the scientific community’s continued interest in AOD-9604 as both a research tool and a compound with diverse potential applications.
References
Ogru E, Wilson JC, Heffernan M, Jiang WJ, Chalmers DK, Libinaki R, Ng F. The conformational and biological analysis of a cyclic anti-obesity peptide from the C-terminal domain of human growth hormone. J Pept Res. 2000;56(6):388-397. doi:10.1034/j.1399-3011.2000.00773.x. PMID: 11152296
Moré MI, Kenley D. Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health. J Endocrinol Metab. 2014;4(3):66-78. doi:10.14740/jem231w
Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189. doi:10.1210/endo.142.12.8522. PMID: 11713213
Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-278. doi:10.1159/000053182. PMID: 11146367
Heffernan MA, Thorburn AW, Fam B, Summers R, Conway-Campbell B, Waters MJ, Ng FM. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001;25(10):1442-1449. doi:10.1038/sj.ijo.0801740. PMID: 11673763
Wu Z, Ng FM. Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone. Biochem Mol Biol Int. 1993;30(1):187-196. PMID: 8358331
Natera SH, Jiang WJ, Ng FM. Reduction of cumulative body weight gain and adipose tissue mass in obese mice: response to chronic treatment with synthetic hGH 177-191 peptide. Biochem Mol Biol Int. 1994;33(5):1011-1021. PMID: 7987246
Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. J Endocrinol Metab. 2013;3(1-2):7-15. doi:10.4021/jem157w
Heffernan MA, Jiang WJ, Thorburn AW, Ng FM. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. Am J Physiol Endocrinol Metab. 2000;279(3):E501-507. doi:10.1152/ajpendo.2000.279.3.E501. PMID: 10950816
Moré MI, Kenley D. Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health. J Endocrinol Metab. 2014;4(3):66-78. doi:10.14740/jem231w
Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189. doi:10.1210/endo.142.12.8522. PMID: 11713213
Ng FM, Jiang WJ, Gianello R, Pitt S, Roupas P. Molecular and cellular actions of a structural domain of human growth hormone (AOD9401) on lipid metabolism in Zucker fatty rats. J Mol Endocrinol. 2000;25(3):287-298. doi:10.1677/jme.0.0250287. PMID: 11116208
Heffernan MA, Jiang WJ, Thorburn AW, Ng FM. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. Am J Physiol Endocrinol Metab. 2000;279(3):E501-507. doi:10.1152/ajpendo.2000.279.3.E501. PMID: 10950816
Gonzalez-Fernandez ML, Perez-Castrillo S, Sanchez-Lazaro JA, et al. Peptides for Targeting Chondrogenic Induction and Cartilage Repair. Int J Mol Sci. 2024;25(21):11556. doi:10.3390/ijms252111556
Thomas A, Marchand A, Delahaut P, Terlain B, Thevis M, Schänzer W. Detection and in vitro metabolism of AOD9604. Drug Test Anal. 2014;6(10):1040-1045. doi:10.1002/dta.1621. PMID: 25208511
Bidlingmaier M, Suhr J, Ernst A, Wu Z, Keller A, Strasburger CJ. AOD-9604 does not influence the WADA hGH isoform immunoassay. Drug Test Anal. 2013;5(11-12):850-852. doi:10.1002/dta.1557. PMID: 24124033
FDA Presentation – AOD-9604. Pharmacy Compounding Advisory Committee materials. Available at: https://downloads.regulations.gov/FDA-2024-N-4777-0009/attachment_5.pdf
World Anti-Doping Agency. The Prohibited List – International Standard. 2025. Available at: https://www.wada-ama.org/en/prohibited-list
Kreitschmann-Andermahr I, Suarez P, Jennings R, Evers N, Brabant G. GH/IGF-I regulation in obesity–mechanisms and practical consequences in children and adults. Horm Res Paediatr. 2010;73(3):153-160. doi:10.1159/000284355. PMID: 20197666
Davidson MB. Effect of growth hormone on carbohydrate and lipid metabolism. Endocr Rev. 1987;8(2):115-131. doi:10.1210/edrv-8-2-115. PMID: 3301316
Raben MS, Hollenberg CH. Effect of growth hormone on plasma fatty acids. J Clin Invest. 1959;38(3):484-488. doi:10.1172/JCI103824. PMID: 13641397
Ng FM, Bornstein J, Welker C, Zimmet PZ, Taft P. Insulin potentiating action of synthetic peptides relating to the amino terminal sequence of human growth hormone. Diabetes. 1974;23(12):943-949. doi:10.2337/diab.23.12.943. PMID: 4435306
Caliceti P, Veronese FM, Joasson L. AOD9604, a peptide for the treatment of obesity. Expert Opin Investig Drugs. 2006;15(7):817-828. doi:10.1517/13543784.15.7.817. PMID: 16625817
Wittert GA, Ng FM. Potential role of new therapies in modifying cardiovascular risk in overweight patients. Vasc Health Risk Manag. 2006;2(2):125-134. PMID: 16931496
All products mentioned in this article are sold strictly for laboratory and research purposes only. Not for human consumption. Consult applicable regulations in your jurisdiction before purchasing research materials. The information presented here is a review of published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations.
About Iron Peak Peptides: Iron Peak Peptides is a leading supplier of high-purity research peptides in the United States. All products undergo strict quality standards and are accompanied by comprehensive quality assurance. Browse our complete catalog of research-grade peptides, including AOD 9604, HGH Fragment 176-191, Sermorelin, and many more.
